Wed. 8 May 2024, 6:54am ET
Benzinga
Biotech, Earnings, News, Health Care, General
- Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million.
- The full-year 2024 net cash used in operating activities is expected to be in the range of $110 million to $130 million and assumes the 2023 R&D tax credit is received in 4Q 2024.